Venetoclax and Lintuzumab-Ac225 in AML Patients
Acute Myeloid Leukemia, Relapsed Adult AML

About this trial
This is an interventional treatment trial for Acute Myeloid Leukemia focused on measuring Lintuzumab-Ac225, Venetoclax, Lintuzumab, Refractory AML
Eligibility Criteria
Inclusion Criteria:
Refractory or relapsed AML which will include:
- Refractory disease will be defined as at least 1 prior treatment with no remission.
- Relapsed disease will be defined as 5% or more blasts in bone marrow seen after remission.
- Patients with AML arising from myelodysplastic syndromes (including CMML) or myeloproliferative neoplasms (secondary AML, ts-AML) are also eligible.
- Circulating blast count ≤ 200/μL within 10 days prior to first cycle of treatment. Hydroxyurea should be used to keep the peripheral blast count ≤ 200/μL until the first day of protocol treatment, to the extent that this is possible
- ECOG ≤ 2
- Estimated creatinine clearance ≥ 50 mL/min
- AST and ALT ≤ 3.0 x ULN
- Bilirubin ≤ 3.0 x ULN
Exclusion Criteria:
- Active CNS Leukemia.
- Known HIV infection or known hepatitis B or hepatitis C infection (with a detectable viral load).
- Participant has received strong and/or moderate CYP3A inducers within 7 days prior to the initiation of study treatment.
Secondary refractory AML (e.g., treated for current relapse without achieving remission);
a. With the exception that single agent FLT3 inhibitors, IDH1/IDH2 inhibitors are allowed for current relapse without achieving remission.
- Have received prior radiation to maximally tolerated levels to any critical normal organ.
- Clinically significant cardiac disease.
- Active, uncontrolled serious infection.
- Have other non-myeloid malignancy within 2 years of entry (with exceptions).
- Psychiatric disorder that would preclude study participation
- Previous solid organ transplant (prior treatment with SCT is allowed but not if patient has GVHD or is still receiving immunosuppression/GVHD therapy).
Sites / Locations
- University of CaliforniaRecruiting
- University of LouisvilleRecruiting
- Ochsner Clinic FoundationRecruiting
- Weill Cornell MedicineRecruiting
- Fred Hutchinson Cancer Research CenterRecruiting
Arms of the Study
Arm 1
Experimental
Phase I and Phase II
Lintuzumab-Ac225 administered on Day 5 of each cycle for four cycles (unless in the 0.5 μCi/kg or 0.25 μCi/kg cohorts, where there is a potential for an additional four cycles, pending PI and Medical Monitor review). Venetoclax taken on Days 1-21 of each cycle for up to 12 cycles. Each cycle is 28 days, with a potential to expand to 42 days to allow for full hematologic recovery.